

- 11 Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W: Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. *Mol Pharmacol* 1990;38:567-572.
- 12 Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W: Action of 2',2'-difluorodeoxycytidine on DNA synthesis. *Cancer Res* 1991;51:6110-6117.
- 13 Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W: Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: A mechanism of self-potential. *Cancer Res* 1992;52:533-539.
- 14 Bouffard DY, Labiberte J, Momparler RL: Kinetic studies on 2',2'-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. *Biochem Pharmacol* 1993;45:1857-1861.
- 15 Neff T, Blau CA: Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. *Exp Hematol* 1996;24:1340-1346.
- 16 Eda H, Ura M, F-Ouchi K, Tanaka Y, Miwa M, Ishitsuka H: The antiproliferative activity of DMDC is modulated by inhibition of cytidine deaminase. *Cancer Res* 1998;8:1165-1169.
- 17 Miwa M, Eda H, Ura M, Ouchi KF, Keith DD, Foley LH, Ishitsuka H: High susceptibility of human cancer xenografts with higher levels of cytidine deaminase to a 2'-deoxycytidine antimetabolite, 2'-deoxy-2'-methylidenecytidine. *Clin Cancer Res* 1998;4:493-497.
- 18 Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. *Cancer Res* 1998;58:685-690.
- 19 Kirch HC, Schröder J, Hoppe H, Esche H, Seeber S, Schutte J: Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. *Exp Hematol* 1998;26:421-425.
- 20 Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. *J Biol Chem* 1951;193:265-275.
- 21 Schröder JK, Kirch C, Seeber S, Schutte J: Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. *Br J Haematol* 1998;103:1096-1103.
- 22 Schröder JK, Kirch C, Flasshove M, Kalweit H, Seidelmann M, Hilger R, Seeber S, Schutte J: Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro. *Leukemia* 1996;10:1919-1924.
- 23 Lau KM, LaSpina M, Long J, Ho SM: Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: Regulation by methylation and involvement in growth regulation. *Cancer Res* 2000;60:3175-3182.
- 24 Nishida M, Hino A, Mori K, Matsumoto T, Yoshikubo T, Ishitsuka H: Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. *Biol Pharm Bull* 1996;19:1407-1411.
- 25 Mori K, Hasegawa M, Nishida M, Toma H, Fukuda M, Kubota T, Nagasue N, Yamana H, Hirakawa YS, Chung K, Ikeda T, Takasaki K: Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. *Int J Oncol* 2000;17:33-38.
- 26 Spears CP, Shahinian AH, Moran RG, Heidelberg C, Corbett TH: In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. *Cancer Res* 1982;42:450-456.
- 27 Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. *Cancer Res* 1996;56:2602-2606.
- 28 Marunaka T, Umeno Y, Yoshida K, Nagamachi M, Minami Y, Fujii S: High-pressure liquid chromatographic determination of fluorafur [1-(tetrahydro-2-furanyl)-5-fluorouracil] and GLC-mass spectrometric determination of 5-fluorouracil and uracil in biological materials after oral administration of uracil plus fluorafur. *J Pharm Sci* 1980;69:1296-1300.
- 29 Ahmed SA, Gogal RM Jr, Walsh JE: A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: An alternative to <sup>3</sup>H-thymidine incorporation assay. *J Immunol Methods* 1994;170:211-224.
- 30 Morita T, Tokue A: Biomodulation of 5-fluorouracil by interferon alpha in human renal carcinoma cells: Relation to the expression of thymidine phosphorylase. *Cancer Chem Pharm* 1999;44:91-96.
- 31 Veerman G, Ruiz van Haperen VW, Vermorcken JB, Noordhuis P, Braakhuis BJ, Pinedo HM, Peters GJ: Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors. *Cancer Chemother Pharmacol* 1996;38:335-342.
- 32 Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. *Cancer Res* 1998;58:685-690.
- 33 Reigner B, Verweij J, Dirix L, Cassidy J, Twelves C, Allman D, Weidekamm E, Roos B, Banken L, Utoh M, Osterwalder B: Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. *Clin Cancer Res* 1998;4:941-948.
- 34 Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T: Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine. *J Clin Oncol* 1998;16:1795-1802.
- 35 Morita T, Matsuzaki A, Suzuki K, Tokue A: Role of thymidine phosphorylase in biomodulation of fluoropyrimidines. *Curr Pharm Biotechnol* 2001;2:257-267.
- 36 Morita T, Matsuzaki A, Tokue A: Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA. *Int J Cancer* 2001;92:451-456.
- 37 Hidalgo M, Castellano D, Paz-Ares L, Gravalos C, Diaz-Puente M, Hitt R, Alonso S, Cortes-Funes H: Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. *J Clin Oncol* 1999;17:585-592.
- 38 Rini BI, Vogelzang NJ, Dumas MC, Wade JL 3rd, Taber DA, Stadler WM: Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. *J Clin Oncol* 2000;18:2419-2426.
- 39 Mani S, Vogelzang NJ, Bertucci D, Stadler WM, Schilsky RL, Ratain MJ: Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: A potential broadly active regimen for advanced solid tumor malignancies. *Cancer* 2001;92:1567-1576.
- 40 Herrmann R, Borner M, Morant RAD, Roth AD, Ludwig C, Bedoucha V: Combining gemcitabine (GEM) and capecitabine (CAP) in advanced pancreatic cancer. *Proc Am Soc Clin Oncol* 2000;19:267a.
- 41 Schilsky RL, Bertucci D, Vogelzang NJ, Kindler HL, Ratain MJ: Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. *J Clin Oncol* 2002;20:582-587.